(E)-2-methyl-N-(3-morpholinopropyl)-3-phenylprop-2-en-1-amine | 1375800-63-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (E)-2-methyl-N-(3-morpholinopropyl)-3-phenylprop-2-en-1-amine
• 英文别名: (E)-2-methyl-N-(3-morpholin-4-ylpropyl)-3-phenylprop-2-en-1-amine
• CAS: 1375800-63-7
• 化学式: C₁₇H₂₆N₂O
• 分子量: 274.406
• InChiKey: MJCLMJHYNURURC-JQIJEIRASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-2-methyl-N-(3-morpholinopropyl)-3-phenylprop-2-en-1-amine 、 3,4,5-三甲氧基苯甲酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 1-羟基苯并三唑 作用下， 以 四氢呋喃 为溶剂， 反应 21.5h， 以73%的产率得到(E)-3,4,5-trimethoxy-N-(2-methyl-3-phenylallyl)-N-(3-morpholinopropyl)-benzamide
  参考文献：
  名称：

  Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists

  摘要：

  The chemokine receptor CXCR7 is an atypical G protein-coupled receptor as it preferentially signals through the beta-arrestin pathway rather than through G proteins. CXCR7 is thought to be of importance in cancer and the development of CXCR7-targeting ligands is of huge importance to further elucidate the pharmacology and the therapeutic potential of CXCR7. In the present study, we synthesized 24 derivatives based on a compound scaffold patented by Chemocentryx and obtained CXCR7 ligands with pK(i) values ranging from 5.3 to 8.1. SAR studies were supported by computational 3D Fingerprint studies, revealing several important affinity descriptors. Two key compounds (29 and 30, VUF11207 and VUF11403) were found to be high-potency ligands that induce recruitment of beta-arrestin2 and subsequent internalization of CXCR7, making them important tool compounds in future CXCR7 research. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.041
• 作为产物：
  描述：

  反式-alpha-甲基肉桂醛 在 sodium tetrahydroborate 、 magnesium sulfate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 97.17h， 生成 (E)-2-methyl-N-(3-morpholinopropyl)-3-phenylprop-2-en-1-amine
  参考文献：
  名称：

  Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists

  摘要：

  The chemokine receptor CXCR7 is an atypical G protein-coupled receptor as it preferentially signals through the beta-arrestin pathway rather than through G proteins. CXCR7 is thought to be of importance in cancer and the development of CXCR7-targeting ligands is of huge importance to further elucidate the pharmacology and the therapeutic potential of CXCR7. In the present study, we synthesized 24 derivatives based on a compound scaffold patented by Chemocentryx and obtained CXCR7 ligands with pK(i) values ranging from 5.3 to 8.1. SAR studies were supported by computational 3D Fingerprint studies, revealing several important affinity descriptors. Two key compounds (29 and 30, VUF11207 and VUF11403) were found to be high-potency ligands that induce recruitment of beta-arrestin2 and subsequent internalization of CXCR7, making them important tool compounds in future CXCR7 research. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.041

文献信息

• INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2
  申请人：Melikian Anita

  公开号：US20100144720A1

  公开（公告）日：2010-06-10

  Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

  本发明涉及含有有机化合物或其盐的制药组合物，其作为SDF-1或I-TAC趋化因子的调节剂。这些化合物和组合物在癌症治疗中特别是在抑制癌症增殖、生长和转移方面具有用途。本发明还揭示了干扰SDF-1和/或I-TAC与CCXCKR2受体结合以及使用本发明的化合物和制药组合物治疗癌症的方法。
• US7649011B2
  申请人：——

  公开号：US7649011B2

  公开（公告）日：2010-01-19